Prot# KAN-979-01: An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 with Newly Diagnosed Acute Myeloid Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date2/1/06 → 4/1/12

Funding

  • Kanisa Pharmaceuticals, Inc. (KAN-979-01)